New Evidence Suggests a Lack of Cost-Shifting in Prescription Drug Markets
Guest Post
February 17, 2022
Some worry that proposals to regulate drug prices in Medicare will cause drug manufacturers to “make up” lost revenues in the unconstrained commercial market. We summarize arguments for and against this theory.
